Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Thromb Haemost. 2015 Jan 15;113(3):473–481. doi: 10.1160/TH14-06-0507

Figure 6. Influence of pro- and anti-inflammatory agonists on the release of eRNA and TNF-α from BMDM.

Figure 6

A) Following treatment of BMDM (M2-phenotype) for 6 h with IL-4, eRNA or LPS in the absence or presence of RNase1 (1 µg/ml) as indicated, eRNA in cell supernatants was quantified using the NanoDrop ND-2000. Values represent mean ± SD (n=3), **p<0.01; ns=non-significant, nd=not detectable. B) Following treatment of BMDM for 24 h with IL-4, LPS, eRNA or hydrolysed eRNA (eRNA + RNase1) alone or in combination as indicated, TNF-α protein in cell supernatants was quantified by ELISA. Values correspond to mean ± SD from three independent experiments, each carried out in triplicate, *p<0.05, **p<0.01; ns=non-significant.